Dilated cardiomyopathy overview
|
Dilated cardiomyopathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dilated cardiomyopathy overview On the Web |
|
American Roentgen Ray Society Images of Dilated cardiomyopathy overview |
|
Risk calculators and risk factors for Dilated cardiomyopathy overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-in-Chief: Abdelrahman Ibrahim Abushouk, MD[2]; Sachin Shah, M.D.
Overview
Dilated cardiomyopathy (DCM) is defined by the presence of left ventricular (LV) or biventricular dilatation with systolic dysfunction in the absence of abnormal loading conditions (e.g., primary valve disease, uncontrolled hypertension) or significant coronary artery disease sufficient to cause the observed ventricular remodeling. The American Heart Association defines DCM as a spectrum of heterogeneous myocardial disorders characterized by ventricular dilation and depressed myocardial performance in the absence of hypertension, valvular, congenital, or ischemic heart disease.
This conventional definition has been recognized as overly restrictive, because LV hypokinesis without dilatation can represent the initial presentation of DCM. The 2023 European Society of Cardiology (ESC) Cardiomyopathy Guidelines introduced the entity of non-dilated left ventricular cardiomyopathy (NDLVC), defined by non-ischemic LV scarring, fatty replacement, or isolated global hypokinesia without LV dilatation. DCM and NDLVC may represent a continuum, with approximately 29% of NDLVC patients progressing to a DCM phenotype over long-term follow-up.
DCM is one of the most common causes of heart failure and the leading indication for heart transplantation worldwide, with a revised prevalence estimate of approximately 1:220 to 1:250 — far higher than the classic 1:2,500 figure. In pediatric populations, the diagnosis requires body-size-adjusted LV dimensions (z-scores > 2) with reduced systolic function.
Historical Perspective
The understanding of DCM has evolved substantially over the past five decades. The WHO/ISFC initially classified it in 1980 as a "heart muscle disorder of unknown cause," a definition that persisted through the 1995 revision. The AHA 2006 Scientific Statement reclassified cardiomyopathies by etiology (genetic vs. acquired), while the ESC 2008 Position Statement organized them by morphology and hemodynamics. The most recent milestone is the 2023 ESC Cardiomyopathy Guidelines, which formally introduced NDLVC as a distinct entity and refined the phenotypic classification of left ventricular cardiomyopathies.
Therapeutically, the field has progressed from an era of limited options (digoxin, diuretics) through the sequential introduction of ACE inhibitors (1980s–1990s), beta-blockers (1990s–2000s), MRAs, device therapy (ICD, CRT), ARNI (PARADIGM-HF, 2014), and most recently SGLT2 inhibitors (DAPA-HF 2019, EMPEROR-Reduced 2020), establishing the modern four-pillar GDMT paradigm. Concurrently, advances in molecular genetics have transformed DCM from a largely "idiopathic" diagnosis to one with identifiable genetic causes in 25–40% of familial cases.
Pathophysiology
DCM results from diverse molecular insults that converge on a final common pathway of adverse ventricular remodeling — progressive chamber dilatation, eccentric hypertrophy, and systolic dysfunction. Key mechanisms include sarcomeric and cytoskeletal protein dysfunction (e.g., titin truncation, lamin A/C haploinsufficiency), neurohormonal activation (RAAS, sympathetic nervous system, natriuretic peptide system), calcium handling abnormalities, inflammatory and immune-mediated myocardial injury, metabolic derangements, and progressive myocardial fibrosis (both replacement and interstitial).
Fibrosis is a critical substrate for both mechanical dysfunction and ventricular arrhythmias; CMR-detected late gadolinium enhancement (LGE) ≥7.1–7.5% of LV mass independently predicts sudden cardiac death. Genetic mutations translate to the DCM phenotype through mechanisms that vary by gene — for example, TTN truncating variants impair sarcomere assembly, LMNA mutations disrupt nuclear envelope integrity and mechanotransduction, and DSP variants compromise desmosomal cell–cell adhesion.
Causes
DCM results from a heterogeneous mix of genetic and acquired causes, with frequent gene–environment interactions.
- Genetic causes: Account for 25–40% of familial and 10–30% of apparently sporadic cases. The most commonly implicated genes are TTN (15–25% of familial DCM), LMNA (~5–6%), MYH7, FLNC, DSP, RBM20, BAG3, PLN, SCN5A, and DES. Inheritance is most commonly autosomal dominant with age-dependent and incomplete penetrance.
- Acquired causes: Include viral myocarditis, alcohol and substance use, anthracycline chemotherapy, peripartum cardiomyopathy, tachycardia-mediated cardiomyopathy, endocrine disorders (thyroid disease), autoimmune/inflammatory conditions, Chagas disease, nutritional deficiencies, and toxin exposure.
- Gene-Environment Overlap: Importantly, 5–15% of patients with apparently acquired DCM harbor a pathogenic genetic variant, underscoring the need to consider both genetic and acquired factors in every patient.
- Idiopathic DCM: Classified when no cause is identified after comprehensive evaluation. Historically accounted for ~50% of cases but is steadily declining as genetic testing yield improves.
Epidemiology and Demographics
- Prevalence: Early echocardiographic studies estimated ~1:2,500; more recent CMR- and genetics-informed estimates suggest approximately 1:220 to 1:250.
- Incidence: Approximately 5–7 per 100,000 persons per year, with considerable geographic variation.
- Sex: Consistent male-to-female ratio of approximately 2:1 across all subtypes. This ratio is partially attributable to underdiagnosis in women when sex-specific imaging thresholds are not applied.
- Race/Ethnicity: African Americans have an approximately 3-fold increased risk of developing DCM and 1.5- to 2-fold higher mortality compared with age-matched White patients, independent of hypertension and socioeconomic factors.
- Age: Most commonly presents in the third to fourth decade of life; in children, infants younger than 12 months have the highest incidence.
- Temporal trends: Nationwide registry studies demonstrate increasing prevalence over the past two decades, with striking excess mortality seen in younger patients.
Screening
- Clinical Screening: First-degree relatives of any patient with DCM should undergo clinical cardiovascular screening (history, ECG, echocardiography) at recommended intervals of every 3–5 years in adults, with increased frequency if abnormalities are detected or if the proband was diagnosed at a young age.
- Cumulative Risk: The cumulative risk of a first-degree relative developing DCM or a partial phenotype (LV enlargement or systolic dysfunction alone) by age 80 is estimated at ~33%.
- Cascade Genetic Testing: Should be offered when a pathogenic/likely pathogenic variant is identified in the proband; relatives who do not carry the variant can be released from lifelong surveillance.
Natural History, Complications and Prognosis
- Survival and Recovery: Historical data reported 5-year survival of ~50%, but contemporary outcomes have improved substantially with GDMT and device therapy. Approximately 25% of patients with recent-onset symptoms experience spontaneous improvement, but those with symptoms lasting >3 months and severe decompensation have a lower probability of recovery.
- Mortality: Sudden cardiac death occurs in up to 12% of patients and accounts for approximately one-quarter to one-third of all DCM-related deaths; pump failure accounts for the remaining two-thirds.
- Prognostic Predictors: Key prognostic predictors include LVEF, NYHA functional class, RV involvement, diastolic dysfunction severity, BNP/NT-proBNP levels, myocardial scar burden on CMR (LGE ≥7.1–7.5% of LV mass), and genetic subtype.
- Genotype Impact: LMNA and desmosomal variants confer the highest arrhythmic risk, whereas TTN truncating variants are associated with better prognosis and higher rates of LV reverse remodeling.
- Complications: Include progressive heart failure, functional mitral and tricuspid regurgitation, atrial fibrillation, ventricular arrhythmias, thromboembolism (stroke, peripheral embolism), and sudden cardiac arrest.
Diagnosis
The diagnostic evaluation of DCM involves a systematic, multimodal approach.
History and Symptoms
Common presenting symptoms include dyspnea (exertional and at rest), orthopnea, paroxysmal nocturnal dyspnea, fatigue, exercise intolerance, peripheral edema, palpitations, and syncope/presyncope. Thromboembolic events (stroke, peripheral embolism) may be the initial presentation. A careful history should evaluate for family history of cardiomyopathy or sudden death (≥3 generations), viral prodrome, alcohol and substance use, chemotherapy exposure, pregnancy, HIV risk factors, autoimmune disease, and medication/toxin exposure. DCM is also frequently discovered incidentally in asymptomatic individuals during screening or unrelated imaging.
Laboratory Findings
The laboratory workup targets both etiologic identification and prognostic assessment. Core studies include BNP/NT-proBNP (diagnosis and prognosis), cardiac troponin (myocyte injury), comprehensive metabolic panel (renal/hepatic function, electrolytes), CBC, thyroid function tests, iron studies (ferritin, TSAT), and fasting glucose/HbA1c. Targeted testing based on clinical suspicion includes autoimmune serologies (ANA, anti-dsDNA), viral serologies, HIV testing, toxicology screening, serum CK (neuromuscular disease), and genetic counseling/testing.
MRI
Cardiac MRI (CMR) is the gold standard for volumetric assessment and provides unique tissue characterization. Key findings include LV dilatation (indexed LVEDVi above sex-specific thresholds), reduced LVEF, and characteristic nonischemic LGE patterns (midwall or subepicardial, most commonly in the interventricular septum) that distinguish DCM from ischemic cardiomyopathy (subendocardial/transmural LGE in a coronary territory). T1 and T2 mapping detect diffuse fibrosis and myocardial edema, respectively. CMR is particularly valuable for identifying myocarditis (Lake Louise criteria), infiltrative diseases, and genotype-specific scar patterns.
Echocardiography
Echocardiography is the first-line imaging modality for diagnosing DCM. Characteristic findings include LV dilatation (increased LVEDD and LVESD), globally reduced LVEF by biplane Simpson's method, and diffuse hypokinesis (though focal wall motion abnormalities may occur). Additional findings include LA dilatation, functional mitral regurgitation, RV dilatation and dysfunction, diastolic dysfunction (elevated E/e' ratio), and intracardiac thrombus. Global longitudinal strain (GLS) by speckle-tracking echocardiography provides incremental prognostic value beyond LVEF and may detect subclinical dysfunction before overt dilatation.
Other Diagnostic Studies
- Genetic testing: Recommended for patients with nonischemic cardiomyopathy, particularly those with a family history or clinical features suggesting a genetic etiology. Cascade testing of first-degree relatives is recommended when a pathogenic/likely pathogenic variant is identified.
- Endomyocardial biopsy (EMB): Reserved for specific clinical scenarios where histologic diagnosis would change management—such as suspected giant cell myocarditis, eosinophilic myocarditis, cardiac sarcoidosis, or unexplained rapidly progressive heart failure.
- Coronary evaluation: Coronary CTA or invasive angiography is essential to exclude ischemic etiology in all new DCM diagnoses.
- Right heart catheterization: Utilized for hemodynamic assessment in patients being evaluated for advanced therapies (LVAD, transplant) or when filling pressures are uncertain.
- Ambulatory ECG monitoring: Holter or event monitoring to assess arrhythmia burden, particularly in patients with palpitations, syncope, or genetic subtypes with high arrhythmic risk (e.g., LMNA).
Treatment
Medical Therapy
Management of DCM follows the framework for HFrEF, with etiology-specific considerations. Quadruple GDMT ("four pillars") is foundational:
- ARNI (sacubitril/valsartan) or ACEi/ARB
- Evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol)
- Mineralocorticoid receptor antagonist (spironolactone or eplerenone)
- SGLT2 inhibitor (dapagliflozin or empagliflozin)
Compared with no treatment, comprehensive quadruple therapy reduces the estimated risk of death by approximately 73% over 2 years. Additional agents include hydralazine/isosorbide dinitrate (particularly in self-identified Black patients), ivabradine (for persistent sinus tachycardia ≥70 bpm on maximally tolerated beta-blocker), vericiguat (for worsening HF), diuretics for congestion, and digoxin for symptom control. Etiology-specific therapies include alcohol cessation, rate/rhythm control for tachycardia-mediated cardiomyopathy, immunosuppression for select inflammatory cardiomyopathies, and genotype-informed decisions.
Surgery
- Implantable cardioverter-defibrillator (ICD): Indicated for primary prevention of SCD in patients with LVEF ≤35% despite ≥3 months of optimal GDMT.
- Cardiac resynchronization therapy (CRT): Indicated for patients with LVEF ≤35%, LBBB with QRS ≥150 ms, and NYHA class II–IV symptoms despite optimal GDMT.
- Left ventricular assist device (LVAD): Bridge to transplant or destination therapy for patients with refractory end-stage heart failure.
- Heart transplantation: Definitive therapy for patients with end-stage DCM refractory to medical and device therapy; listing criteria include peak VO₂ <12–14 mL/kg/min or dependence on inotropes/mechanical support.
- Transcatheter mitral valve repair: May be considered for select patients with severe secondary mitral regurgitation and persistent symptoms despite optimal GDMT.